---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-213436"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2023-08-15T23:59:59+00:00"
generated_at: "2026-06-11T09:29:41.090670+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Frequency Therapeutics terminates two leases, ending all lease obligations at 75 Hayden Ave by Jan 31, 2024 without cost

## Summary
- Terminated Master Lease with LS 75 Hayden LLC effective Jan 31, 2024 (originally through May 31, 2031).
- Terminated Sublease with Saliogen Therapeutics effective Jan 31, 2024 (originally through July 31, 2024).
- Company is not subject to any payments or costs under either termination agreement.

## SEC filing metadata
- accession: 0001193125-23-213436
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2023-08-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312523213436/0001193125-23-213436-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312523213436/d493024d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-213436
- JSON: https://secwatch.observer/filing/0001193125-23-213436.json
- Plain text: https://secwatch.observer/filing/0001193125-23-213436.txt

## Key facts
- Material Agreements
  Korro Bio, Inc. terminated Sublease Agreement with Saliogen Therapeutics, Inc. valued at No payments or costs (effective 2024-01-31).
  - Action: termination
  - Agreement: lease
  - Counterparty: Saliogen Therapeutics, Inc.
  - Value: No payments or costs
  - Effective: 2024-01-31
  source text: Also on August 11, 2023, the Company entered into a Sublease Termination Agreement with Saliogen Therapeutics, Inc. (“Subtenant”), pursuant to which the parties agreed to terminate that certain Sublease Agreement, by and between the Company and Subtenant, dated as of July 8, 2022 (the “Sublease”), on January 31, 2024 (the “Sublease Termination Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312523213436/0001193125-23-213436-index.htm
- Material Agreements
  Korro Bio, Inc. terminated Indenture of Lease (Master Lease) with LS 75 Hayden LLC valued at No payments or costs (effective 2024-01-31).
  - Action: termination
  - Agreement: lease
  - Counterparty: LS 75 Hayden LLC
  - Value: No payments or costs
  - Effective: 2024-01-31
  source text: On August 11, 2023, Frequency Therapeutics, Inc. (the “Company”) entered into a Termination Agreement with LS 75 Hayden LLC (“Landlord”) for certain premises located at 75 Hayden Avenue, Lexington, Massachusetts (the “Lease Termination Agreement”). The Lease Termination Agreement provides that the Indenture of Lease (the “Master Lease”), dated as of January 7, 2020, by and between the Company and the Landlord will terminate on January 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312523213436/0001193125-23-213436-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.